Who are Neodrol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nexplanon, Ortho-Cept, Danzol, Nandrolone Decanoate, Aldocorten, Intrarosa.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/androstanolone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Neodrol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neodrol (androstanolone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: androstanolone. Area: Hematology.

unknown androstanolone Sex hormone-binding globulin Hematology Live · refreshed every 30 min

Target snapshot

Neodrol (androstanolone). Neodrol works by binding to androgen receptors, mimicking the effects of natural androgens like testosterone.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Neodrol TARGET	androstanolone		unknown	androstanolone	Sex hormone-binding globulin
Nexplanon	ETONOGESTREL		marketed	Estrogen [EPC]	Sex hormone-binding globulin	2001-01-01
Ortho-Cept	DESOGESTREL	Merck & Co.	marketed	Progestin	Sex hormone-binding globulin	1992-01-01
Danzol	DANAZOL		marketed	Androgen [EPC]	Sex hormone-binding globulin	1976-01-01
Nandrolone Decanoate	NANDROLONE DECANOATE	Woodward Specl	marketed	Androgen	Sex hormone-binding globulin	1962-01-01
Aldocorten	ALDOSTERONE		marketed	Gonadotropin [EPC]	Corticosteroid-binding globulin, Sex hormone-binding globulin, Mineralocorticoid receptor
Intrarosa	PRASTERONE		marketed	Non-Standardized Food Allergenic Extract [EPC]	Sex hormone-binding globulin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (androstanolone class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Neodrol — Competitive Intelligence Brief. https://druglandscape.com/ci/androstanolone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing